Clasado Biosciences has shared insight from its scientific portfolio on the connection between prebiotics and immune function.
As a result of the scientific backing behind its unique prebiotic galactooligosaccharide (GOS) ingredient, Bimuno® GOS, the business projects a significant potential role for prebiotics in supporting immune function and in particular, addressing inflammation.
The most studied prebiotic of its kind, the safety and efficacy of Bimuno GOS is supported by more than 100 scientific publications, including more than 20 clinical trials.
Dr Lucien Harthoorn, R&D Director at Clasado Biosciences, explains: “Prebiotics nourish beneficial bacteria in the gut, but the advantages go far beyond digestive health. Our gut microbiome influences many other key areas of health, too. The research portfolio behind Bimuno GOS is the strongest on the market, giving us fantastic insight into the potential role of prebiotics in supporting immune function.
“When talking immunomodulation – one of the key areas of focus is inflammation – Bimuno GOS is shown to be advantageous across three key channels. These are systemic inflammation, where the prebiotic shows positive impact on some of the main biomarkers of inflammation as well as an increase in anti-inflammatory markers; gut inflammation where our prebiotic is shown to display positive impact on gut inflammatory markers; and neuroinflammation, where anti-inflammatory capacity is also shown through in vivo studies.
“The upshot is that Bimuno GOS is shown to increase anti-inflammatory and reduce pro-inflammatory molecules, and as we look to the future of immune health and what that looks like for the consumer, there’s clear evidence for the future of prebiotics. We are beginning to uncover the enormous and widespread benefits of a better supported gut microbiome, and the good gut bacteria that support the body in new ways we are discovering through extensive research.”
According to statistics published by intelligence firm Grand View Research, the global market for prebiotics is set to experience an extremely strong compound annual growth rate (CAGR) of 14.9% to 2030, buoyed by surging consumer interest in gut health.
Dr Frederic Narbel, VP of B2B Sales at Clasado, comments: “Following acceleration through Covid-19, consumers are switching on to immune health supporting products. With around 70% of the immune system residing in the gut, prebiotics make a very natural building block for formulators looking to tap into this newly engaged market.
“With Bimuno GOS, we make it extremely simple to formulate immune-supporting products with leading prebiotic technology, which includes approved health claims in select territories, such as Australia and New Zealand, for example. Designed for versatility and performance, Bimuno GOS has a low efficacious dose, which provides additional formulating flexibility as well as being more consumer friendly in terms of serving sizes. Its stability makes it ideal for a wide range of product applications as the immune health category expands and diversifies.
“As the world looks to the future of health and wellbeing, immunity is set to remain high on the agenda. The evidence connecting prebiotics and immune function is strong, so there’s no better time to explore an advanced prebiotic ingredient like Bimuno GOS.”
To learn more about Clasado Biosciences and the scientific portfolio behind Bimuno GOS, please visit www.clasado.com